The path toward therapeutic psychedelic-based drugs is becoming clearer as scientists understand more about how they are processed in the body.
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
Sensitive to LSD? It may be in your genes.
How do psychedelics interact with the human body beyond brain cells?
A deep dive into the strengths and limitations of the trial.
Was psilocybin really effective for treating depression?
A look at some fundamental ideas defining these intriguing compounds.
Properties of psychedelics determine optimal routes of administration.
Blocking the 5-HT2A receptor helps researchers understand psychedelics.
It's likely to follow the compounds that fast track through the clinical psychedelic renaissance.